A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM PRODIGE 63 GERCOR study)

ANNÉE

2019

AUTEURS

Neuzillet C, Hautefeuille V, Lambert A, Garcia-Larnicol ML, Vernerey D

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES